NL-OMON38491撤回不适用
The prevalence of the IGSF-1 mutation in children who develop central hypothyroidism after starting Growth Hormone treatment. - The prevalence of the IGSF-1 mutation
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 27
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 2 至 17（—）
入选标准
- •Children receiving thyroxine within two years after starting growth hormone treatment.
排除标准
- •Children with isolated Growth Hormone deficiency ( not using thyroxine ) or children already known with Multiple Pituitary Hormone deficiency at the moment of starting growth hormone treatment.
研究者
相似试验
已完成
3 期
Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The AgeFetal Growth RetardationNCT00174252Pfizer57
尚未招募
Unknown
In this study healthy children and adolescents of 5-16 years are group are taken to determine chronological age bone age and correlate them with serum IGF-1 levels.CTRI/2024/05/067782Jawaharlal Nehru Medical College, KLE University, Belagavi
尚未招募
不适用
What are the common and uncommon gene mutations among cystic fibrosis children in south IndiaCTRI/2022/12/047881Aster CMI Hospital
进行中（未招募）
不适用
PASS of Paediatric Patients Initiating SelumetinibNeurofibromatosis Type 1NCT05388370AstraZeneca124
已完成
2 期
Pioglitazone in the treatment of acromegalyMetabolic and Endocrine - Metabolic disordersAcromegalyACTRN12610000780055Auckland district health board20